Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer

Metastatic prostate cancer continues to kill approximately 30,000 men per year. Since 2010, five new therapeutic agents have been Food and Drug Administration (FDA) approved to treat metastatic castration-resistant prostate cancer (mCRPC). With the increasing number of therapies available to clinici...

Full description

Bibliographic Details
Main Authors:	Markowski, Mark C, Pienta, Kenneth J
Format:	Online
Language:	English
Published:	Medknow Publications & Media Pvt Ltd 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814966/

id	pubmed-4814966
recordtype	oai_dc
spelling	pubmed-48149662016-04-19 Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer Markowski, Mark C Pienta, Kenneth J Invited Opinion Metastatic prostate cancer continues to kill approximately 30,000 men per year. Since 2010, five new therapeutic agents have been Food and Drug Administration (FDA) approved to treat metastatic castration-resistant prostate cancer (mCRPC). With the increasing number of therapies available to clinicians, the most effective sequence in which to implement these treatments remains unknown. The presence or absence of symptoms (i.e., bony pain, visceral crisis) is a key parameter that informs the decision-making process regarding therapy. Treatment algorithms based on: 1) asymptomatic/minimal symptoms, 2) moderate symptoms or chemotherapy ineligible or 3) symptomatic disease need to be developed. Medknow Publications & Media Pvt Ltd 2015 2015-04-10 /pmc/articles/PMC4814966/ /pubmed/25865849 http://dx.doi.org/10.4103/1008-682X.150843 Text en Copyright: © Asian Journal of Andrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Markowski, Mark C Pienta, Kenneth J
spellingShingle	Markowski, Mark C Pienta, Kenneth J Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
author_facet	Markowski, Mark C Pienta, Kenneth J
author_sort	Markowski, Mark C
title	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
title_short	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
title_full	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
title_fullStr	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
title_full_unstemmed	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
title_sort	therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
description	Metastatic prostate cancer continues to kill approximately 30,000 men per year. Since 2010, five new therapeutic agents have been Food and Drug Administration (FDA) approved to treat metastatic castration-resistant prostate cancer (mCRPC). With the increasing number of therapies available to clinicians, the most effective sequence in which to implement these treatments remains unknown. The presence or absence of symptoms (i.e., bony pain, visceral crisis) is a key parameter that informs the decision-making process regarding therapy. Treatment algorithms based on: 1) asymptomatic/minimal symptoms, 2) moderate symptoms or chemotherapy ineligible or 3) symptomatic disease need to be developed.
publisher	Medknow Publications & Media Pvt Ltd
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814966/
_version_	1613560173612236800

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer

Similar Items